FMTX News and Press, Forma Therapeutics Holdings Inc. From 08/13/21

Significant progress achieved with pipeline focused on rare hematologic diseases and cancers Positive Phase 1 results in patients with sickle cell disease (SCD) presented at European Hematology Association (EHA) Virtual Congress supporting etavopivat’s potential to sign...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release second quarter 2021 financial results Friday, Aug. 13, 2021. Forma management will host an investment c...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

The following slide deck was published by Forma Therapeutics Holdings, Inc. in conjunction with this event. For further details see: Forma Therapeutics Holdings (FMTX) EHA Investor Presentation - Slideshow

Lone Pine Capital’s 13F portfolio value increased marginally from $27.51B to $27.53B. The number of positions decreased from 41 to 38. They increased Facebook, Microsoft, and DoorDash while dropping DocuSign, Autodesk, and Humana. The top three positions are Shopify, Micros...

goir/iStock via Getty Images Goldman Sachs estimates Biogen to reach above $600 Projecting $28.4B of peak sales for newly-approved Alzheimer’s therapy aducanumab, Goldman Sachs analysts led by Terence Flynn expects Biogen (BIIB) shares to reach $639.00 apiece indicating a premium of ~6...

Forma Therapeutics Holdings (FMTX) announces the appointment of industry veteran John Bishop as senior vice president and chief technology officer.In this role, Bishop will lead chemistry, manufacturing and control ((CMC))-related functions and quality, encompass...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of John E. Bishop, Ph.D., to the leadership team as senior vice president and chief technology officer. In t...

Gainers: Novan (NOVN) +74%.Urban One (UONE) +39%.Iconix Brand (ICON) +28%.Aptinyx (APTX) +24%.Carver Bancorp (CARV) +22%.Vaxart (VXRT) +21%.Xinyuan Real Estate (XIN) +20%Broadway Financial (BYFC) +18%.Amesite (AMST) +18%.Siebert Financial (SIEB) +16%.Losers: Recon Technolo...

Chan2545/iStock via Getty Images Forma Therapeutics ([[FMTX]] -20.9%) is trading sharply lower in morning hours after the company announced new data from its ongoing Phase 1 trial of etavopivat (formerly referred to as FT-4202) in patients with sickle cell disease ((SCD)). The resul...